



Proteomics International

LABORATORIES LTD

ASX Release

12 April 2022

ASX code: PIQ

New Clinical Advisory Board to support PromarkerD global rollout

- **Proteomics International establishes world class Clinical Advisory Board**
- **Comprises highly-respected physicians specialising in diabetes and kidney disease care from the United States, Europe and Australia**
- **New advisory board offers doctors' viewpoint in commercialisation of the PromarkerD blood test for the prediction of diabetic kidney disease**
- **Doctors will ultimately order PromarkerD for diabetes patients with the advisory board able to provide specific and tailored advice from the voice of the customer perspective**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to announce it has assembled a team of world leading clinicians specialising in nephrology and endocrinology to advise the Company on its clinical and commercial initiatives towards a successful launch of the PromarkerD test for diabetic kidney disease to physicians globally.

The clinicians—from the United States, Europe and Australia—are global experts in diabetes technology and care, and influential key opinion leaders (KOLs) in their respective fields. Together, they form a world class clinical advisory board to offer expert opinion on the best strategies for the market rollout of PromarkerD from a doctor's viewpoint.

The engagement of the Clinical Advisory Board builds upon a powerful clinical utility study that demonstrated the PromarkerD predictive test for diabetic kidney disease (DKD) can help inform doctors' treatment decisions and improve clinical outcomes for patients with type 2 diabetes [ASX 18 Oct 21]. Ultimately it is physicians that will order the PromarkerD test for their patients, and generate sales for Proteomics International.

Proteomics International Managing Director Dr Richard Lipscombe said, *"Our new Clinical Advisory Board will provide a great insight into what doctors, being the end users of the product, regard as the key topics for the successful rollout of PromarkerD globally, so it's critical to have their perspective."*

Proteomics International Chief Commercialisation Officer Vik Malik said we are excited with the recruitment of world-class clinical thought leaders in the fields of endocrinology and nephrology to serve as our global brand ambassadors and provide validation towards our clinical and commercial initiatives.

"Wide adoption of PromarkerD testing could inform doctors' treatment decisions to help avoid end-stage interventions such as dialysis and kidney transplant in patients with type 2 diabetes, and this offers potentially significant benefit to patient quality of life and cost savings for healthcare systems. We are looking forward to our KOLs providing specific and tailored advice from the voice of the customer perspective to assist the rollout of the PromarkerD test to the world," he said.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

The Clinical Advisory Board comprises seven highly-respected physicians, researchers and thought leaders, from some of the world's top hospitals and universities specialising in the care of diabetes and its complications.

Clinical Advisory Board

Professor Tim Davis [BMedSc, MB, W.Aust., DPhil Oxf., FRACP, MRCP (UK)]

Australia

Professor Tim Davis is a consultant physician and endocrinologist at Fremantle Hospital, and professor of medicine at The University of Western Australia. He was awarded the Lifetime Achievement Award by the Australian Diabetes Society in 2021 for more than 40 years of research in diabetes. He has sat on numerous federal and state government advisory committees, and involvement with leading advocacy groups for diabetes care.

Formerly a councillor of the Australian Diabetes Society, Professor Davis now co-leads the WA Health Department's Diabetes and Endocrinology Clinical Network. He is principal investigator of the Fremantle Diabetes Studies, comprising a community-based cohort for large-scale prospective and longitudinal studies in diabetes. Professor Davis also continues to engage in global collaborations and regularly reviews papers for leading diabetes journals.

Dr Ele Ferrannini [MD]

Italy

Dr Ele Ferrannini is a professor of medicine at the University of Pisa, an adjunct clinical professor of medicine at the University of Texas Health Science Center, and a senior research associate at the National Research Council's Institute of Clinical Physiology. He is the 2020 recipient of the American Diabetes Association's Banting Medal for Scientific Achievement, in recognition of his significant, long-term contributions to the understanding, treatment and prevention of diabetes.

Dr Ferrannini is renowned for his contributions to insulin resistance and associated disorders, β -cell function and dysfunction in vivo, the incretin effect, and the cardiovascular complications of diabetes. Dr Ferrannini has also done pioneering work in therapeutics, including DPP-4 and SGLT2 inhibition and bariatric surgery, receiving recognition on the Clarivate™ list of Highly Cited Researchers.

Dr David Kerr [MBChB, DM, FRCP, FRCP (Edin)]

United States

David Kerr MD is the Director of Research and Innovation at the Sansum Diabetes Research Institute in Santa Barbara, California. Prior to this, he was Consultant Physician at Bournemouth Diabetes and Endocrine Center in the UK during which time he held a Gold Clinical Excellence Award for services to the National Health Service (NHS). Dr. Kerr is also the digital health lead for the Diabetes Technology Society.

His most recent endeavours focus on reducing the disproportionate burden of diabetes in underserved communities, particularly US Hispanic/Latino families, through the nexus of digital health technologies and democratizing knowledge. Dr. Kerr has published more than 400 articles and commentaries and has Google Scholar h-index of 50.

Clinical Professor David Klonoff [MD, FACP, FRCP (Edin), Fellow AIMBE]

United States

David Klonoff is a Clinical Professor of Medicine at the University of California at San Francisco and an endocrinologist specialising in bioengineered solutions for people with diabetes. In 2001, he established the Diabetes Technology Society to accelerate positive changes in diabetes care. Klonoff

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

has led many multi-stakeholder technical and clinical standards projects including for continuous glucose monitor data (Clinical Laboratory Standards Institute), hospital guidelines for using continuous glucose monitors and automated insulin dosing systems (Diabetes Technology Society), and cybersecurity for wireless diabetes devices (IEEE). He is co-chair of the iCoDE standard project to integrate continuous glucose monitor data into the electronic health record. He is the only person in the world to be an advisor or investigator for all four manufacturers of the first four non-invasive glucose monitors to receive a CE Mark.

Klonoff has been awarded the American Diabetes Association's Outstanding Physician Clinician Award, and an FDA Director's Special Citation Award for outstanding contributions to diabetes technology. He is currently focusing on improved health outcomes using novel drugs, wearable sensors, mobile apps, and new metrics for analysing data.

Associate Professor Michael Shanik [MD, FACP, FACE]

United States

Associate Professor Michael Shanik is managing partner at Endocrine Associates of Long Island, PC and a clinical associate professor at Stony Brook University Hospital, New York. Dr Shanik has been an invited speaker at regional, national, and international meetings. He serves as principal investigator for many studies in diabetes and metabolism. Research interests include diabetes and cardiovascular and renal outcomes, major cardiovascular events, and novel therapies for diabetes.

Associate Professor Shanik earned his medical degree from New York Medical College and completed residency training in internal medicine at Long Island Jewish Medical Center, followed by a fellowship in endocrinology, diabetes and metabolism at North Shore-Long Island Jewish Health System. He is board certified in internal medicine, as well as endocrinology, diabetes and metabolism.

Professor Merlin Thomas [MBChB, PhD, FRACP, FAAHMS]

Australia

Professor Merlin Thomas is a nephrologist, scientist and program leader in the Department of Diabetes at Monash University. He is founder and chief scientific officer of RAGE Biotech Ltd, and a Fellow of the Australian Academy of Health Medical Science. He is a leader in his field, publishing Nature review articles on the pathophysiology and management of diabetic kidney disease.

Dr Thomas is renowned as a researcher and educator with over 300 peer-reviewed publications, as well as the author of best-selling books *The Longevity List* and *Fast Living Slow Ageing*. His research focuses on the mechanisms of diabetic complications and new opportunities for their prevention and treatment.

Dr Alexander Turchin [MD, MS]

United States

Dr Alexander Turchin is the director of quality for the division of endocrinology at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School. His research focuses on the treatment of patients with chronic cardiometabolic conditions using advanced electronic medical record data analytics, including causal inference, artificial intelligence and predictive modelling.

Dr Turchin is an immediate past chair of healthcare delivery and quality improvement interest group at the American Diabetes Association, and a member of the methods and data council at AcademyHealth. He is a Fellow of the American College of Medical Informatics and has been recognized as a Top Doctor by Boston Magazine. Dr Turchin has published over 100 papers and book chapters.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Vik Malik
Chief Commercialisation Officer
Proteomics International
T: +1 312 310 4444
E: vik.malik@proteomics.com.au

Investors

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com